

Ajay Pratap Singh

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8852876/ajay-pratap-singh-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61
papers

2,194
citations

28
h-index

46
g-index

64
ext. papers

2,671
ext. citations

5.8
avg, IF

5.09
L-index

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 61 | Determining the Size Distribution and Integrity of Extracellular Vesicles by Dynamic Light Scattering.. <i>Methods in Molecular Biology</i> , 2022 , 2413, 165-175 | 1.4 | 0 |
| 60 | MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer. <i>British Journal of Cancer</i> , 2021 , | 8.7 | 1 |
| 59 | Nicotine causes alternative polarization of macrophages via Src-mediated STAT3 activation: Potential pathobiological implications. <i>Journal of Cellular Physiology</i> , 2021 , | 7 | 3 |
| 58 | Clinicopathologic significance and race-specific prognostic association of MYB overexpression in ovarian cancer. <i>Scientific Reports</i> , 2021 , 11, 12901 | 4.9 | 2 |
| 57 | The impact of neoadjuvant concurrent chemoradiation on exosomal markers (CD63 and CD9) expression and their prognostic significance in patients with rectal adenocarcinoma. <i>Oncotarget</i> , 2021 , 12, 1490-1498 | 3.3 | 0 |
| 56 | Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1330, 1-19 | 3.6 | 0 |
| 55 | The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens. <i>Pharmacogenomics Journal</i> , 2021 , 21, 308-317 | 3.5 | 0 |
| 54 | Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management. <i>Seminars in Cancer Biology</i> , 2021 , 77, 99-109 | 12.7 | 5 |
| 53 | Extracellular Nanovesicles: From Intercellular Messengers to Efficient Drug Delivery Systems. <i>ACS Omega</i> , 2021 , 6, 1773-1779 | 3.9 | 5 |
| 52 | Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer. <i>Journal of Biological Chemistry</i> , 2020 , 295, 8413-8424 | 5.4 | 18 |
| 51 | Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy. <i>Seminars in Cancer Biology</i> , 2020 , | 12.7 | 9 |
| 50 | Proteomic Analysis of MYB-Regulated Secretome Identifies Functional Pathways and Biomarkers: Potential Pathobiological and Clinical Implications. <i>Journal of Proteome Research</i> , 2020 , 19, 794-804 | 5.6 | 7 |
| 49 | Dysregulation of metabolic enzymes in tumor and stromal cells: Role in oncogenesis and therapeutic opportunities. <i>Cancer Letters</i> , 2020 , 473, 176-185 | 9.9 | 12 |
| 48 | Resistin: An inflammatory cytokine with multi-faceted roles in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020 , 1874, 188419 | 11.2 | 12 |
| 47 | Comprehensive Analysis of Expression, Clinicopathological Association and Potential Prognostic Significance of RABs in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 8 |
| 46 | Exosomal Formulation Escalates Cellular Uptake of Honokiol Leading to the Enhancement of Its Antitumor Efficacy. <i>ACS Omega</i> , 2020 , 5, 23299-23307 | 3.9 | 9 |
| 45 | Cellular and Molecular Progression of Prostate Cancer: Models for Basic and Preclinical Research. <i>Cancers</i> , 2020 , 12, | 6.6 | 9 |

| | | | |
|----|--|------|-----|
| 44 | Hypoxia alters the release and size distribution of extracellular vesicles in pancreatic cancer cells to support their adaptive survival. <i>Journal of Cellular Biochemistry</i> , 2020 , 121, 828-839 | 4.7 | 53 |
| 43 | Drug-loaded exosomal preparations from different cell types exhibit distinctive loading capability, yield, and antitumor efficacies: a comparative analysis. <i>International Journal of Nanomedicine</i> , 2019 , 14, 531-541 | 7.3 | 56 |
| 42 | Epigallocatechin Gallate-Gold Nanoparticles Exhibit Superior Antitumor Activity Compared to Conventional Gold Nanoparticles: Potential Synergistic Interactions. <i>Nanomaterials</i> , 2019 , 9, | 5.4 | 21 |
| 41 | Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications. <i>Scientific Reports</i> , 2019 , 9, 5335 | 4.9 | 229 |
| 40 | Looking at cancer health disparities without the colored lenses. <i>Cancer Health Disparities</i> , 2019 , 3, e1-e9 | 1.1 | 1 |
| 39 | Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope. <i>Cancers</i> , 2019 , 12, | 6.6 | 23 |
| 38 | Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages. <i>Scientific Reports</i> , 2018 , 8, 12000 | 4.9 | 33 |
| 37 | Exosomes 2018 , 261-283 | | 2 |
| 36 | Epigenetic basis of cancer health disparities: Looking beyond genetic differences. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017 , 1868, 16-28 | 11.2 | 26 |
| 35 | Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. <i>British Journal of Cancer</i> , 2017 , 116, 609-619 | 8.7 | 159 |
| 34 | MicroRNAs in gynecological cancers: Small molecules with big implications. <i>Cancer Letters</i> , 2017 , 407, 123-138 | 9.9 | 67 |
| 33 | Resistin potentiates chemoresistance and stemness of breast cancer cells: Implications for racially disparate therapeutic outcomes. <i>Cancer Letters</i> , 2017 , 396, 21-29 | 9.9 | 28 |
| 32 | Racial health disparities in ovarian cancer: not just black and white. <i>Journal of Ovarian Research</i> , 2017 , 10, 58 | 5.5 | 13 |
| 31 | Racial disparities in prostate cancer: a molecular perspective. <i>Frontiers in Bioscience - Landmark</i> , 2017 , 22, 772-782 | 2.8 | 57 |
| 30 | Hydroxytyrosol Induces Apoptosis and Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells. <i>Nutrition and Cancer</i> , 2017 , 69, 932-942 | 2.8 | 37 |
| 29 | Cancer Chemoprevention by Phytochemicals: Nature's Healing Touch. <i>Molecules</i> , 2017 , 22, | 4.8 | 75 |
| 28 | Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward. <i>International Journal of Molecular Sciences</i> , 2017 , 18, | 6.3 | 42 |
| 27 | Deep sequencing and in silico analyses identify MYB-regulated gene networks and signaling pathways in pancreatic cancer. <i>Scientific Reports</i> , 2016 , 6, 28446 | 4.9 | 19 |

| | | | |
|----|--|------|----|
| 26 | Cancer Stem Cells 2016 , 375-413 | | 3 |
| 25 | Glucose Metabolism Reprogrammed by Overexpression of IKK β Promotes Pancreatic Tumor Growth. <i>Cancer Research</i> , 2016 , 76, 7254-7264 | 10.1 | 26 |
| 24 | MYB Promotes Desmoplasia in Pancreatic Cancer through Direct Transcriptional Up-regulation and Cooperative Action of Sonic Hedgehog and Adrenomedullin. <i>Journal of Biological Chemistry</i> , 2016 , 291, 16263-70 | 5.4 | 14 |
| 23 | p-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes in pancreatic cancer cells through activation of STAT3 signaling. <i>Cancer Letters</i> , 2016 , 370, 260-7 | 9.9 | 50 |
| 22 | Pancreatic Cancer Exosomes: Shedding Off for a Meaningful Journey. <i>Pancreatic Disorders & Therapy</i> , 2016 , 6, e148 | | 33 |
| 21 | Mobilization of Intracellular Copper by Gossypol and Apogossypolone Leads to Reactive Oxygen Species-Mediated Cell Death: Putative Anticancer Mechanism. <i>International Journal of Molecular Sciences</i> , 2016 , 17, | 6.3 | 13 |
| 20 | Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumor-stromal cross-talk. <i>Carcinogenesis</i> , 2016 , 37, 1052-1061 | 4.6 | 25 |
| 19 | Comparative analysis of the relative potential of silver, Zinc-oxide and titanium-dioxide nanoparticles against UVB-induced DNA damage for the prevention of skin carcinogenesis. <i>Cancer Letters</i> , 2016 , 383, 53-61 | 9.9 | 45 |
| 18 | Silver nanoparticles protect human keratinocytes against UVB radiation-induced DNA damage and apoptosis: potential for prevention of skin carcinogenesis. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015 , 11, 1265-75 | 6 | 55 |
| 17 | MicroRNA-345 induces apoptosis in pancreatic cancer cells through potentiation of caspase-dependent and -independent pathways. <i>British Journal of Cancer</i> , 2015 , 113, 660-8 | 8.7 | 51 |
| 16 | Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation. <i>Oncotarget</i> , 2015 , 6, 11231-41 | 3.3 | 76 |
| 15 | Modulation of microRNAs by phytochemicals in cancer: underlying mechanisms and translational significance. <i>BioMed Research International</i> , 2015 , 2015, 848710 | 3 | 42 |
| 14 | MYB is a novel regulator of pancreatic tumour growth and metastasis. <i>British Journal of Cancer</i> , 2015 , 113, 1694-703 | 8.7 | 35 |
| 13 | Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2015 , 889, 71-87 | 3.6 | 36 |
| 12 | Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications. <i>Oncotarget</i> , 2015 , 6, 39140-50 | 3.3 | 17 |
| 11 | MicroRNAs in pancreatic malignancy: progress and promises. <i>Cancer Letters</i> , 2014 , 347, 167-74 | 9.9 | 45 |
| 10 | Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy. <i>International Journal of Nanomedicine</i> , 2014 , 9, 2933-42 | 7.3 | 42 |
| 9 | CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1. <i>Oncotarget</i> , 2014 , 5, 11490-500 | 3.3 | 44 |

| | | | |
|---|---|-----|-----|
| 8 | Molecular Targets of Honokiol: A Promising Phytochemical for Effective Cancer Management. <i>The Enzymes</i> , 2014 , 36, 175-93 | 2.3 | 9 |
| 7 | p-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells through AKT- and ERK-dependent activation of NF- κ B pathway. <i>Oncotarget</i> , 2014 , 5, 8778-89 | 3.3 | 90 |
| 6 | An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κ B- and hypoxia-inducible factor 1 α -mediated up-regulation of CXCR4. <i>Journal of Biological Chemistry</i> , 2013 , 288, 21197-21207 | 5.4 | 122 |
| 5 | CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor κ B: implications for bidirectional tumor-stromal interactions. <i>Journal of Biological Chemistry</i> , 2012 , 287, 39115-24 | 5.4 | 92 |
| 4 | Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance. <i>Carcinogenesis</i> , 2012 , 33, 1149-57 | 4.6 | 39 |
| 3 | Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. <i>PLoS ONE</i> , 2011 , 6, e21573 | 3.7 | 104 |
| 2 | Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 720-31 | 6.1 | 45 |
| 1 | microRNAs in Cancer Stem Cells: Micromanagers of Malignancy 269-284 | | |